Department of Endocrinology and EMGO Institute for Health and Care Research, VU University Medical Center, Amsterdam, The Netherlands.
Clin Endocrinol (Oxf). 2010 Sep;73(3):277-85. doi: 10.1111/j.1365-2265.2009.03701.x.
Studies of vitamin D and calcium for fracture prevention have produced inconsistent results, as a result of different vitamin D status and calcium intake at baseline, different doses and poor to adequate compliance. This study tries to define the types of patients, both at risk of osteoporosis and with established disease, who may benefit from calcium and vitamin D supplementation. The importance of adequate compliance in these individuals is also discussed. Calcium and vitamin D therapy has been recommended for older persons, either frail and institutionalized or independent, with key risk factors including decreased bone mineral density (BMD), osteoporotic fractures, increased bone remodelling as a result of secondary hyperparathyroidism and increased propensity to falls. In addition, treatment of osteoporosis with a bisphosphonate was less effective in patients with vitamin D deficiency. Calcium and vitamin D supplementation is a key component of prevention and treatment of osteoporosis unless calcium intake and vitamin D status are optimal. For primary disease prevention, supplementation should be targeted to those with dietary insufficiencies. Several serum 25-hydroxyvitamin D (25(OH)D) cut-offs have been proposed to define vitamin D insufficiency (as opposed to adequate vitamin D status), ranging from 30 to 100 nmol/l. Based on the relationship between serum 25(OH)D, BMD, bone turnover, lower extremity function and falls, we suggest that 50 nmol/l is the appropriate serum 25(OH)D threshold to define vitamin D insufficiency. Supplementation should therefore generally aim to increase 25(OH)D levels within the 50-75 nmol/l range. This level can be achieved with a dose of 800 IU/day vitamin D, the dose that was used in successful fracture prevention studies to date; a randomized clinical trial assessing whether higher vitamin D doses achieve a greater reduction of fracture incidence would be of considerable interest. As calcium balance is not only affected by vitamin D status but also by calcium intake, recommendations for adequate calcium intake should also be met. The findings of community-based clinical trials with vitamin D and calcium supplementation in which compliance was moderate or less have often been negative, whereas studies in institutionalized patients in whom medication administration was supervised ensuring adequate compliance demonstrated significant benefits.
关于维生素 D 和钙预防骨折的研究结果并不一致,这是由于基线时维生素 D 状态和钙摄入量不同、给予的剂量不同以及依从性差或不足。本研究旨在确定可能从钙和维生素 D 补充中获益的患者类型,包括有骨质疏松症风险和已确诊疾病的患者。还讨论了这些个体中充分依从的重要性。钙和维生素 D 治疗已被推荐用于老年人,无论其身体虚弱、住院还是独立生活,关键的危险因素包括骨密度降低(BMD)、骨质疏松性骨折、继发性甲状旁腺功能亢进导致的骨重建增加以及跌倒倾向增加。此外,维生素 D 缺乏的患者使用双膦酸盐治疗骨质疏松症的效果较差。除非钙摄入量和维生素 D 状况最佳,否则钙和维生素 D 补充是预防和治疗骨质疏松症的关键组成部分。对于原发性疾病预防,补充应针对那些饮食摄入不足的人。已经提出了几种血清 25-羟维生素 D(25(OH)D)切点来定义维生素 D 不足(与充足的维生素 D 状态相反),范围从 30 到 100 nmol/L。基于血清 25(OH)D、BMD、骨转换、下肢功能和跌倒之间的关系,我们建议 50 nmol/L 是定义维生素 D 不足的合适血清 25(OH)D 阈值。因此,补充通常应旨在将 25(OH)D 水平提高到 50-75 nmol/L 范围内。这一水平可以通过每天 800IU 维生素 D 的剂量来实现,这是迄今为止在成功预防骨折的研究中使用的剂量;一项评估更高剂量的维生素 D 是否能更大程度地降低骨折发生率的随机临床试验将非常有意义。由于钙平衡不仅受维生素 D 状态的影响,还受钙摄入量的影响,因此也应满足充足的钙摄入量建议。在社区为基础的临床试验中,维生素 D 和钙补充剂的依从性中等或较差时,结果往往是阴性的,而在住院患者中,药物管理得到监督以确保充分依从性的研究则显示出显著的益处。